Quantum Blue® Calprotectin Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B. Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis. 2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. “FC levels appears
Continue Reading →
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
More than 50 independent publications have proven the clinical performance and reliability of our fecal calprotectin assays in diagnosis and monitoring of IBD patients. The BÜHLMANN fCAL® ELISA can therefore be considered as the gold standard in fecal calprotectin testing. Check out our key literature list now
BÜHLMANN fCAL® ELISA Citation Naismith, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014 Sep;8(9):1022-9. doi: 10.1016/j.crohns.2014.01.029. “The FC result, obtained by non-invasive means, can provide prognostic information for both the patient
Continue Reading →
BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015. “The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up to €2.13 million.”
Social Links